Clinical Practice Guidelines for the Antibiotic Treatment of Community-Acquired Urinary Tract Infections

키워드

참고문헌 (157)

1. "CADTH databases search filters"[URL]
2. Nicolle LE, "Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteri-uria in adults", Clin Infect Dis, 40, pp.643~654 (2005)[DOI]
3. "Guidelines on urological infections"[URL]
4. Dull RB, "Antimicrobial treatment of asymptomatic bacteriuria in noncatheterized adults: a systematic review", Pharmacotherapy, 34, pp.941~960 (2014)[DOI]
5. Nicolle LE, "Asymptomatic bacteriuria", Curr Opin Infect Dis, 27, pp.90~96 (2014)[DOI]
6. Nicolle LE, "The paradigm shift to non-treatment of asymptomatic bacteriuria", Pathogens, 5 (2016)
7. Bengtsson C, "Bacteriuria in a population sample of women: 24-year follow-up study. Results from the prospective population-based study of women in Gothenburg, Sweden", Scand J Urol Nephrol, 32, pp.284~289 (1998)[DOI]
8. Evans DA, "Bacteriuria in a population-based cohort of women", J Infect Dis, 138, pp.768~773 (1978)[DOI]
9. 전민혁, "전국병원감염감시체계 중환자실 부문 결과: 2010년 7월부터 2011년 6월", 의료관련감염관리, 17(1), pp.28~39 (2012), 대한의료관련감염관리학회[DOI]
10. 신지철, "척수손상 환자에서 증상성 요로감염 시 소변 균주와 항생제 감수성의 변화", Annals of Rehabilitation Medicine, 32(1), pp.38~44 (2008), 대한재활의학회
11. Smaill FM, "Antibiotics for asymptomatic bacteriuria in pregnancy", Cochrane Database Syst Rev, (8) (2015)
12. Kazemier BM, "Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial", Lancet Infect Dis, 15, pp.1324~1333 (2015)[DOI]
13. Angelescu K, "Benefits and harms of screening for and treatment of asymptomatic bacteriuria in pregnancy: a systematic review", BMC Pregnancy Childbirth, 16, pp.336~ (2016)[DOI]
14. Cai T, "The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat?", Clin Infect Dis, 55, pp.771~777 (2012)[DOI]
15. Cai T, "Asymptomatic bacteriuria treatment is associated with a higher prevalence of antibiotic resistant strains in women with urinary tract infections", Clin Infect Dis, 61, pp.1655~1661 (2015)
16. Boscia JA, "Therapy vs no therapy for bacteriuria in elderly ambulatory nonhospitalized women", JAMA, 257, pp.1067~1071 (1987)[DOI]
17. Abrutyn E, "Does asymptomatic bacteriuria predict mortality and does antimicrobial treatment reduce mortality in elderly ambulatory women?", Ann Intern Med, 120, pp.827~833 (1994)[DOI]
18. Nicolle LE, "Prospective randomized comparison of therapy and no therapy for asymptomatic bacteriuria in institutionalized elderly women", Am J Med, 83, pp.27~33 (1987)
19. Ouslander JG, "Does eradicating bacteriuria affect the severity of chronic urinary incontinence in nursing home residents?", Ann Intern Med, 122, pp.749~754 (1995)[DOI]
20. Harding GK, "Antimicrobial treatment in diabetic women with asymptomatic bacteriuria", N Engl J Med, 347, pp.1576~1583 (2002)[DOI]
21. Dalal S, "Long-term Escherichia coli asymptomatic bacteriuria among women with diabetes mellitus", Clin Infect Dis, 49, pp.491~497 (2009)[DOI]
22. Mohler JL, "Suppression and treatment of urinary tract infection in patients with an intermittent ly catheterized neurogenic bladder", J Urol, 138, pp.336~340 (1987)[DOI]
23. Maynard FM, "Urinary infection and complications during clean intermittent catheterization following spinal cord injury", J Urol, 132, pp.943~946 (1984)[DOI]
24. Harding GK, "How long should catheter- acquired urinary tract infection in women be treated? a randomized controlled study", Ann Intern Med, 114, pp.713~719 (1991)[DOI]
25. Warren JW, "Cephalexin for susceptible bacteriuria in afebrile, longterm catheterized patients", JAMA, 248, pp.454~458 (1982)[DOI]
26. Leone M, "A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients", Intensive Care Med, 33, pp.726~729 (2007)[DOI]
27. Hooton TM, "Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America", Clin Infect Dis, 50, pp.625~663 (2010)[DOI]
28. Grabe M, "Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery", Eur J Clin Microbiol, 6, pp.11~17 (1987)[DOI]
29. Olsen JH, "Cefotaxime for prevention of infectious complications in bacteriuric men undergoing transurethral prostatic resection. A controlled comparison with methenamine", Scand J Urol Nephrol, 17, pp.299~301 (1983)[DOI]
30. Grabe M, "The effect of a short antibiotic course in transurethral prostatic resection", Scand J Urol Nephrol, 18, pp.37~42 (1984)[DOI]
31. Allan WR, "Prophylactic mezlocillin for transurethral prostatectomy", Br J Urol, 57, pp.46~49 (1985)[DOI]
32. Rao PN, "Prediction of septicemia following endourological manipulation for stones in the upper urinary tract", J Urol, 146, pp.955~960 (1991)[DOI]
33. Cafferkey MT, "Antibiotics for the prevention of septicaemia in urology", J Antimicrob Chemother, 9, pp.471~477 (1982)[DOI]
34. Nicolle LE, "Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis", Urol Clin North Am, 35, pp.1~12 (2008)[DOI]
35. Health Insurance Review & Assessment service, "In-depth analysis of drug consumption", HIRA, ~ (2015)
36. Mazzulli T, "Resistance trends in urinary tract pathogens and impact on management", J Urol, 168, pp.1720~1722 (2002)[DOI]
37. Lee SJ, "Antimicrobial resistance in community-acquired urinary tract infections: results from the Korean Antimicrobial Resistance Monitoring System", J Infect Chemother, 17, pp.440~446 (2011)[DOI]
38. 김봉영, "국내에서 지역사회 급성 신우신염 원인균의 항균제 감수성 결과에 근거하여 지역사회 급성 방광염 치료 항균제를 선택할 수 있는가?", Infection and Chemotherapy, 44(4), pp.269~274 (2012), 대한감염학회
39. Lee SJ, "Antimicrobial susceptibility of uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2002", Int J Antimicrob Agents, 24(Suppl 1), pp.S61~S64 (2004)[DOI]
40. Kim ME, "Prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2006", Int J Antimicrob Agents, 31(Suppl 1), pp.S15~S18 (2008)[DOI]
41. Kim HY, "Microbiological characteristics of unresolved acute uncomplicated cystitis", Microb Drug Resist, 22, pp.387~391 (2016)[DOI]
42. 김웅빈, "Recent Antimicrobial Susceptibilities for Uropathogenic Escherichia coli in Patients with Community Acquired Urinary Tract Infections: A Multicenter Study", Urogenital Tract Infection, 12(1), pp.28~34 (2017), 대한요로생식기감염학회
43. 김경영, "최근 2년간 전라남도 및 광주지역의 지역사회 획득성 요로감염에 이환된 여성 환자에서 동정된 Escherichia coli의 Ciprofloxacin 내성패턴", Investigative and Clinical Urology, 49(6), pp.540~548 (2008), 대한비뇨의학회
44. 대한감염학회, "요로 감염 임상진료지침 권고안: 무증상 세균뇨, 단순 요로감염, 복잡성 요로감염, 세균성 전립선염", Infection and Chemotherapy, 43(1), pp.1~25 (2011), 대한감염학회
45. Bent S, "Does this woman have an acute uncomplicated urinary tract infection?", JAMA, 287, pp.2701~2710 (2002)[DOI]
46. Rowe TA, "Diagnosis and management of urinary tract infection in older adults", Infect Dis Clin North Am, 28, pp.75~89 (2014)[DOI]
47. Simerville JA, "Urinalysis: a comprehensive review", Am Fam Physician, 71, pp.1153~1162 (2005)
48. Rubin RH, "Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration", Clin Infect Dis, 15(Suppl 1), pp.S216~S227 (1992)[DOI]
49. Zalmanovici Trestioreanu A, "Antimicrobial agents for treating uncomplicated urinary tract infection in women", Cochrane Database Syst Rev, (10) (2010)
50. Rafalsky V, "Quinolones for uncomplicated acute cystitis in women", Cochrane Database Syst Rev, (3) (2006)
51. "Fluoroquinolone antimicrobial drugs information"[URL]
52. Falagas ME, "Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials", J Antimicrob Chemother, 65, pp.1862~1877 (2010)[DOI]
53. Schito GC, "The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections", Int J Antimicrob Agents, 34, pp.407~413 (2009)[DOI]
54. Zhanel GG, "Fosfomycin: a firstline oral therapy for acute uncomplicated cystitis", Can J Infect Dis Med Microbiol, 2016, pp.2082693~ (2016)
55. 서미란, "Susceptibility of Escherichia coli from Community-Acquired Urinary Tract Infection to Fosfomycin, Nitrofurantoin, and Temocillin in Korea", Journal of Korean Medical Science, 29(8), pp.1178~1181 (2014), 대한의학회
56. Hooton TM, "Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial", JAMA, 307, pp.583~589 (2012)
57. Kavatha D, "Cefpodoxime-proxetil versus trimethoprim- sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women", Antimicrob Agents and Chemother, 47, pp.897~900 (2003)[DOI]
58. Raz R, "Double- blind study comparing 3-day regimens of cefixime and ofloxacin in treatment of uncomplicated urinary tract infections in women", Antimicrob Agents Chemother, 38, pp.1176~1177 (1994)[DOI]
59. Galkin VV, "Efficacy and safety of cefixim and ciprofloxacin in acute cystitis (a multicenter randomized trial)", Urologiia, (1), pp.13~16 (2011)
60. 이승주, "급성 단순성 방광염의 경험적 치료로써 Cefcapene Pivoxil의 유효성", Infection and Chemotherapy, 40(3), pp.162~166 (2008), 대한감염학회
61. 손동완, "외래 방문 여성 급성 단순성 방광염 환자에서 분리된 Escherichia coli에 대한 경구 항생제의 시험관 내 감수성 연구", Infection and Chemotherapy, 38(3), pp.140~145 (2006), 대한감염학회
62. 노경호, "원외 획득 요로 감염 그람음성 간균에 대한 Cefatrizine-Clavulanic Acid의시험관내 항균력", Annals of Laboratory Medicine, 25(6), pp.411~415 (2005), 대한진단검사의학회
63. 이수영, "소아 원외 요로감염 환아에서 분리된 E. coli에 대한cefixime을 포함한 경구 항생제의 감수성 연구", Clinical and Experimental Pediatrics, 49(7), pp.777~783 (2006), 대한소아청소년과학회
64. Warren JW, "Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA)", Clin Infect Dis, 29, pp.745~758 (1999)[DOI]
65. Kim JH, "Prevalence of antibiotic susceptibility and resistance of Escherichia coli in acute uncomplicated cystitis in Korea: systematic review and meta-analysis", Medicine (Baltimore), 95, pp.e4663~ (2016)[DOI]
66. Pinart M, "Optimal dosage and duration of pivmecillinam treatment for uncomplicated lower urinary tract infections: a systematic review and meta-analysis", Int J Infect Dis, 58, pp.96~109 (2017)[DOI]
67. Milo G, "Duration of antibacterial treatment for uncomplicated urinary tract infection in women", Cochrane Database Syst Rev, (2) (2005)
68. Lutters M, "Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women", Cochrane Database Syst Rev, (3) (2008)
69. Sadahira T, "Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: multicentre, randomized, open-label trial", J Antimicrob Chemother, 72, pp.529~534 (2017)[DOI]
70. Grigoryan L, "Less workup, longer treatment, but no clinical benefit observed in women with diabetes and acute cystitis", Diabetes Res Clin Pract, 129, pp.197~202 (2017)[DOI]
71. Katchman EA, "Three-day vs longer duration of antibiotic treatment for cystitis in women: systematic review and meta-analysis", Am J Med, 118, pp.1196~1207 (2005)[DOI]
72. Lifshitz E, "Outpatient urine culture: does collect i o n technique matter?", Arch Intern Med, 160, pp.2537~2540 (2000)[DOI]
73. Bradbury SM, "Collection of urine specimens in general practice: to clean or not to clean?", J R Coll Gen Pract, 38, pp.363~365 (1988)
74. Barry HC, "Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies", J Fam Pract, 44, pp.49~60 (1997)
75. Carlson KJ, "Management of acute dysuria. A decision-analysis model of alternative strategies", Ann Intern Med, 102, pp.244~249 (1985)[DOI]
76. Foxman B, "Epidemiology of urinary tract infections: incidence, morbidity, and economic costs", Dis Mon, 49, pp.53~70 (2003)[DOI]
77. Kunin CM, "Urinary tract infections in females", Clin Infect Dis, 18, pp.1~10 (1994)[DOI]
78. Hooton TM. Clinical practice, "Uncomplicated urinary tract infection", N Engl J Med, 366, pp.1028~1037 (2012)[DOI]
79. Ki M, "The epidemiology of acute pyelonephritis in South Korea, 1997-1999", Am J Epidemiol, 160, pp.985~993 (2004)[DOI]
80. Scholes D, "Risk factors associated with acute pyelonephritis in healthy women", Ann Intern Med, 142, pp.20~27 (2005)[DOI]
81. Czaja CA, "Update on acute uncomplicated urinary tract infection in women", Postgrad Med, 119, pp.39~45 (2006)[DOI]
82. Ramakrishnan K, "Diagnosis and management of acute pyelonephritis in adults", Am Fam Physician, 71, pp.933~942 (2005)
83. Efstathiou SP, "Acute pyelonephritis in adults: prediction of mortality and failure of treatment", Arch Intern Med, 163, pp.1206~1212 (2003)[DOI]
84. Farrell DJ, "A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection", J Infect, 46, pp.94~100 (2003)[DOI]
85. 위성헌, "2001년부터 2006년까지 지역사회 획득 급성 신우신장염 여성환자의 임상상 및 원인균의 내성 양상", Infection and Chemotherapy, 49(1), pp.9~16 (2007), 대한감염학회
86. 황병연, "서울 강서지역 1개 대학병원에서 성인 급성 신우신염의 원인균과 항생제 감수성", Infection and Chemotherapy, 35(5), pp.277~282 (2003), 대한감염학회
87. Wie SH, "Antibiotic sensitivity of the causative organisms and use of antibiotics in women with community-acquired acute pyelonephritis", Korean J Infect Dis, 34, pp.353~359 (2002)
88. 이하나, "Management of Antibiotic-Resistant Acute Pyelonephritis", Urogenital Tract Infection, 12(3), pp.95~102 (2017), 대한요로생식기감염학회
89. Kim B, "Clinical characteristics of community- acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea", Infection, 41, pp.603~612 (2013)[DOI]
90. Sanchez GV, "In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010", Antimicrob Agents Chemother, 56, pp.2181~2183 (2012)[DOI]
91. Wie SH, "Clinical characteristics predicting early clinical failure after 72 h of antibiotic treatment in women with community- onset acute pyelonephritis: a prospective multicentre study", Clin Microbiol Infect, 20, pp.O721~O729 (2014)[DOI]
92. Wie SH, "Infectious Diseases", pp.225~237 (2014), Koonja Publishing Inc.
93. "ACR Appropriateness <TEX>$Criteria^{(R)}$</TEX>"[URL]
94. Gupta K, "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases", Clin Infect Dis, 52, pp.e103~e120 (2011)[DOI]
95. Neumann I, "Pyelonephritis (acute) in non-pregnant women", BMJ Clin Evid, 2014 (2014)
96. Czaja CA, "Population- based epidemiologic analysis of acute pyelonephritis", Clin Infect Dis, 45, pp.273~280 (2007)[DOI]
97. van der Starre WE, "Treatment duration of febrile urinary tract infections", Curr Infect Dis Rep, 13, pp.571~578 (2011)[DOI]
98. Jeon JH, "Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high", Antimicrob Agents Chemother, 56, pp.3043~3046 (2012)[DOI]
99. Talan DA, "Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial", JAMA, 283, pp.1583~1590 (2000)[DOI]
100. Stamm WE, "Acute renal infection in women: treatment with trimethoprim-sulfamethoxazole or ampicillin for two or six weeks. A randomized trial", Ann Intern Med, 106, pp.341~345 (1987)[DOI]
101. Klausner HA, "A trial of levofloxacin 750 mg once daily for 5 days vs. ciprofloxacin 400 mg and", or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis, 2007, pp.23, 2637~2645
102. Talan DA, "Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis", J Urol, 171, pp.734~739 (2004)[DOI]
103. Cronberg S, "Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime", Scand J Infect Dis, 33, pp.339~343 (2001)[DOI]
104. Wagenlehner FM, "An update on uncomplicated urinary tract infections in women", Curr Opin Urol, 19, pp.368~374 (2009)[DOI]
105. Sandberg T, "Ciprofloxacin for 7 days vs. 14 days in women with acute pyelonephritis: a randomised, open-label and double- blind, placebo-controlled, non-inferiority trial", Lancet, 380, pp.484~490 (2012)[DOI]
106. van Nieuwkoop C, "Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women", BMC Med, 15, pp.70~ (2017)[DOI]
107. U-Im Chang, "Use of cefuroxime for women with community- onset acute pyelonephritis caused by cefuroxime- susceptible or -resistant Escherichia coli", The Korean Journal of Internal Medicine, 31(1), pp.145~155 (2016), 대한내과학회[DOI]
108. 장우임, "Comparison of Second- and Third-Generation Cephalosporin as Initial Therapy for Women with Community-Onset Uncomplicated Acute Pyelonephritis", Yonsei Medical Journal, 56(5), pp.1266~1273 (2015), 연세대학교의과대학[DOI]
109. Bader MS, "An update on the management of urinary tract infections in the era of antimicrobial resistance", Postgrad Med, 129, pp.242~258 (2017)[DOI]
110. Ipekci T, "Clinical and bacteriological efficacy of amikacin in the treatment of lower urinary tract infection caused by extended-spectrum beta- lactamase-producing Escherichia coli or Klebsiella pneumoniae", J Infect Chemother, 20, pp.762~767 (2014)[DOI]
111. Pietrucha-Dilanchian P, "Diagnosis, treatment, and prevention of urinary tract infection", Microbiol Spectr, 4 (2016)
112. Veve MP, "Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum beta-lactamase urinary tract infections", Int J Antimicrob Agents, 48, pp.56~60 (2016)[DOI]
113. Tamma PD, "The use of cefepime for treating AmpC <TEX>${\beta}$<", TEX>-lactamase-producing Enterobacteriaceae, 2013, pp.57, 781~788
114. Wagenlehner FM, "Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program", Clin Infect Dis, 63, pp.754~762 (2016)[DOI]
115. Wagenlehner FM, "Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)", Lancet, 385, pp.1949~1956 (2015)[DOI]
116. Rodriguez-Bano J1, "<TEX>${\beta}$<", TEX>-Lactam, TEX>-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase- producing Escherichia coli: a post hoc analysis of prospective cohorts, pp.Clin Infect Dis, 2012[DOI]
117. Kang CI, "Piperacillin- tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum <TEX>${\beta}$<", TEX>-lactamase-producing Escherichia coli and Klebsiella pneumoniae, 2012, pp.64, 533~534
118. Sung-Yeon Cho, "Amikacin therapy for urinary tract infections caused by extended-spectrum β-lactamaseproducing Escherichia coli", The Korean Journal of Internal Medicine, 31(1), pp.156~161 (2016), 대한내과학회[DOI]
119. Klahr S, "Obstructive nephropathy", Intern Med, 39, pp.355~361 (2000)[DOI]
120. Reyner K, "Urinary obstruction is an important complicating factor in patients with septic shock due to urinary infection", Am J of Emerg Med, 34, pp.694~696 (2016)[DOI]
121. Heyns CF, "Urinary tract infection associated with conditions causing urinary tract obstruction and stasis, excluding urolithiasis and neuropathic bladder", World J Urol, 30, pp.77~83 (2012)[DOI]
122. Kim SC, "A clinical observation on 131 cases of hydronephrosis", Korean J of Urology, 19, pp.89~97 (1978)
123. Romero Culleres G, "Characteristics of urinary tract infections in different patient subpopulations and depending on the bladder emptying system", Actas Urol Esp, 34, pp.251~257 (2010)[DOI]
124. Marien T, "Treatment of the Infected Stone", Urol Clin North Am, 42, pp.459~472 (2015)[DOI]
125. Brown PD, "Management of urinary tract infections associated with nephrolithiasis", Curr Infect Dis Rep, 12, pp.450~454 (2010)[DOI]
126. Roy C, "Emphysematous pyelitis: findings in five patients", Radiology, 218, pp.647~650 (2001)[DOI]
127. Olvera-Posada D, "Emphysematous pyelonephritis: multicenter clinical and therapeutic experience in Mexico", Urology, 83, pp.1280~1284 (2014)[DOI]
128. Somani BK, "Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review", J Urol, 179, pp.1844~1849 (2008)[DOI]
129. Hamasuna R, "Obstructive pyelonephritis as a result of urolithiasis in Japan: diagnosis, treatment and prognosis", Int J Urol, 22, pp.294~300 (2015)[DOI]
130. Wagenlehner FM, "Diagnosis and management for urosepsis", Int J Urol, 20, pp.963~970 (2013)
131. Cha MK, "In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended- spectrum-<TEX>${\beta}$<", TEX>-lactamase-producing Escherichia coli isolates causing bacteremia, 2015, pp.59, 5834~5837
132. Ramsey S, "Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi", J Endourol, 24, pp.185~189 (2010)[DOI]
133. Aboumarzouk OM, "Emphysematous pyelonephritis: Time for a management plan with an evidence-based approach", Arab J Urol, 12, pp.106~115 (2014)[DOI]
134. Huang JJ, "Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis", Arch Intern Med, 160, pp.797~805 (2000)[DOI]
135. Kolla PK, "Clinical profile and outcome of conservatively managed emphysematous pyelonephritis", ISRN Urol, 2012, pp.931982~ (2012)
136. Bjurlin MA, "Clinical outcomes of nonoperative management in emphysematous urinary tract infections", Urology, 79, pp.1281~1285 (2012)[DOI]
137. Nickel JC, "Category III chronic prostatitis", chronic pelvic pain syndrome: insights from the National Institutes of Health Chronic Prostatitis Collaborative Research Network studies, 2008, pp.9, 320~327
138. Weidner W, "Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1,461 patients", Infection, 19(Suppl 3), pp.S119~S125 (1991)[DOI]
139. Nickel JC, "Asymptomatic inflammation and", or infection in benign prostatic hyperplasia, 1999, pp.84, 976~981
140. Nelson WG, "The role of inflammation in the pathogenesis of prostate cancer", J Urol, 172, pp.S6~S11 (2004)[DOI]
141. Krieger JN, "NIH consensus definition and classification of prostatitis", JAMA, 282, pp.236~237 (1999)[DOI]
142. Leigh DA, "Prostatitis--an increasing clinical problem for diagnosis and management", J Antimicrob Chemother, 32(Suppl A), pp.1~9 (1993)
143. Ludwig M, "Diagnosis and therapy of acute prostatitis, epididymitis and orchitis", Andrologia, 40, pp.76~80 (2008)[DOI]
144. Kravchick S, "Acute prostatitis in middle-aged men: a prospective study", BJU Int, 93, pp.93~96 (2004)[DOI]
145. Ha US, "Acute bacterial prostatitis in Korea: clinical outcome, including symptoms, management, microbiology and course of disease", Int J Antimicrob Agents, 31(Suppl 1), pp.S96~S101 (2008)[DOI]
146. Brede CM, "The etiology and management of acute prostatitis", Nat Rev Urol, 8, pp.207~212 (2011)[DOI]
147. Sharp VJ, "Prostatitis: diagnosis and treatment", Am Fam Physician, 82, pp.397~406 (2010)
148. Groen J, "Summary of European Association of Urology (EAU) guidelines on Neuro-Urology", Eur Urol, 69, pp.324~333 (2016)[DOI]
149. Lipsky BA, "Treatment of bacterial prostatitis", Clin Infect Dis, 50, pp.1641~1652 (2010)[DOI]
150. Etienne M, "Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis", BMC Infect Dis, 8, pp.12~ (2008)[DOI]
151. Charalabopoulos K, "Penetration of antimicrobial agents into the prostate", Chemotherapy, 49, pp.269~279 (2003)[DOI]
152. Millan-Rodriguez F, "Acute bacterial prostatitis: two different sub-categories according to a previous manipulation of the lower urinary tract", World J Urol, 24, pp.45~50 (2006)[DOI]
153. Nickel JC, "The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia", Urology, 62(3 Suppl 1), pp.34~41 (2003)
154. Wagenlehner FM, "Bacterial prostatitis", World J Urol, 31, pp.711~716 (2013)[DOI]
155. Yoon BI, "Acute bacterial prostatitis: how to prevent and manage chronic infection?", J Infect Chemother, 18, pp.444~450 (2012)[DOI]
156. Meares EM Jr, "Prostatic abscess", J Urol, 136, pp.1281~1282 (1986)[DOI]
157. Meares EM Jr, "Acute and chronic prostatitis: diagnosis and treatment", Infect Dis Clin North Am, 1, pp.855~873 (1987)

관련 논문AI추천